Prellis Biologics has raised $35 million and appointed a new CEO as it seeks to advance the development of its proprietary 3D bioprinted lymph node. Raised via a Series C funding round led by Ce…
Prellis Biologics has raised $35 million and appointed a new CEO as it seeks to advance the development of its proprietary 3D bioprinted lymph node. Raised via a Series C funding round led by Ce…